Anavex Life Sciences to Release Fiscal 2024 Fourth Quarter Financial Results

Anavex Life Sciences Corp. ( "Anavex" ) has announced that it will share its financial results for the fourth quarter of its fiscal year ending September 30, 2024. This announcement is set for Monday, December 23, 2024.

Webcast and Conference Call Scheduled

The management team will conduct a conference call at 8:30 am ET on the same day to discuss the financial results. They will also provide updates on the company's growth strategy. After the presentation, participants will have the chance to ask questions.

Accessing the Call

To listen to the live conference call, participants can visit the Anavex website. The call can also be accessed by phone within the U.S. by dialing 1-929-205-6099, using Meeting ID# 814 6482 4038 and reference passcode 336064. A replay of the call will be available on Anavex’s website for up to 30 days following the event.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) focuses on developing new treatments for central nervous system disorders such as Alzheimer's disease, Parkinson's disease, and Rett syndrome. Their lead drug candidate, ANAVEX^®2-73 (blarcamesine), has shown promise in clinical trials for Alzheimer's disease and is being developed to help with various neurodegenerative disorders.

With several successful trials completed, ANAVEX^®2-73 is designed to restore brain function by interacting with specific receptors in the brain, which may protect and improve cognitive health. Moreover, another potential drug candidate, ANAVEX^®3-71, shows promise in addressing the core issues of Alzheimer's disease.

Looking Ahead

As the financial results are forthcoming, Anavex continues to pave the way for innovative treatments in the field of biotechnology, aiming to bring solutions to patients suffering from debilitating diseases. Such advancements highlight the company's commitment to not only financial success but also to improving patient health outcomes.

Forward-Looking Statements

Certain statements in this announcement are forward-looking and involve various risks. Actual outcomes may vary from predictions due to different factors, and stakeholders are advised to view these statements with caution.

Contact Information

For further inquiries, interested parties can contact Anavex Life Sciences Corp. or reach out to their investor relations team for additional details.

Anavex, Finance, Earnings